Spyre Therapeutics Inc (NAS:SYRE)
$ 36.93 1.74 (4.94%) Market Cap: 1.49 Bil Enterprise Value: 1.33 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 34/100

Aeglea Bio Therapeutics Inc Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency Call Transcript

Dec 06, 2021 / 01:00PM GMT
Release Date Price: $95.25 (-36.50%)
Operator

Greetings, and welcome to the Aeglea BioTherapeutics PEACE Phase III Topline Study Results. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Kelly Boothe, Head of Corporate Communications and Investor Relations for Aeglea BioTherapeutics. Thank you. You may begin.

Kelly Boothe
Aeglea BioTherapeutics, Inc. - Senior Director of Corporate Communications & IR

Thank you, operator, and good morning, everyone. Joining me on today's call to discuss the PEACE Phase III topline results are Dr. Anthony Quinn, Chief Executive Officer; Dr. Eric Bradford, Chief Development Officer; Michael Hanley, Chief Commercial Officer; Dr. Leslie Sloan, Chief Operating Officer; and Jonathan Alspaugh, Chief Financial Officer.

The Form 8-K with our press release was filed this morning and is available on the SEC's EDGAR system and on our website. I would like to remind you that various remarks that we make on this call include forward-looking statements for the purposes of the safe harbor

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot